Skip to main content

CluePoints Receives € 6million Growth Investment

By July 23, 2015March 9th, 2022No Comments

growth investment

Funding will grow both operations and business development in the U.S

23 July 2015

Cambridge, MA – CluePoints, a leading software provider of risk-based monitoring (RBM) solutions for clinical trials, has today announced that it has secured a €6million investment to support its future growth, technology innovation and expansion. The new funding will allow CluePoints to grow both operations and business development in the U.S, and enable the company to continue expanding its portfolio of industry-leading monitoring solutions.

The funding has been secured from a combination of private and public investors including CluePoints founder Marc Buyse, former CEO of UCB, Roch Doliveux, and Belgium-based SRIW, Theodorus and Nivelinvest, and will allow CluePoints to further its leading position in the growing RBM market, and build its relationships with regulatory agencies.

CluePoints’ Central Statistical Monitoring (CSM) algorithms provide an agnostic approach to RBM that uses statistical methodology to identify unexpected or unusual patterns in clinical trial databases. Through its patented software engine, SMART™, CSM has the powerful ability to identify anomalous data and site errors, allowing improvement in clinical data quality, optimization of on-site monitoring and a significant reduction in overall regulatory submission risk.

CluePoints’ CEO, Franҫois Torche, comments: “CluePoints has been instrumental in driving a new way of thinking across the industry in terms of RBM techniques, with many of the top 10 pharmaceutical companies now utilizing CSM technology in their clinical trials. Our Central Monitoring Platform’s specialized capability to process both clinical data and operational data to build the next generation of Key Risk Indicators (KRIs), is providing the most comprehensive solution in the field. As we continue to strengthen not only our software but also our consulting arm with industry-leading experts, this investment is a big step forward for us and will allow us to accelerate our plans and enhance our standing as the only provider of CSM technology in the industry.”

For further information on CluePoints’ solutions, please visit

About CluePoints
CluePoints® is a Central Statistical Monitoring solution that has been designed and perfected over the last 10 years. It employs unique statistical algorithms to determine the quality, accuracy and integrity of clinical trial data both during and after study conduct. Aligned with guidance from the FDA and EMA, CluePoints® is deployed to support traditional on-site monitoring and to drive a risk-based monitoring strategy. The value of using CluePoints® lies in its powerful and timely ability to identify anomalous data and site errors allowing improvement in clinical data quality, optimization of on-site monitoring and a significant reduction in overall regulatory submission risk.

Media contact
Patrick Hughes – Chief Commercial Officer, CluePoints
[email protected]
+44 (0) 7703 532 749

Patrick Hughes

Patrick holds a Marketing degree from the University of Newcastle-upon-Tyne, UK, and a post-graduate Marketing diploma in Business-to-Business Marketing Strategy from Northwestern University - Kellogg School of Management, Chicago, Illinois. Responsible for leading global sales, product, marketing, operational and technical teams throughout his career, Patrick is a Senior Executive with over eighteen years international commercial experience within life sciences, healthcare and telecommunications. In the past, Patrick consulted on corporate and commercial strategy for various life sciences companies and was responsible for successfully positioning ClinPhone as the leading Clinical Technology Organization during his 10-year tenure with the company.